01 10Fragmin
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 253
2018 Revenue in Millions : 293
Growth (%) : -14
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 252
2019 Revenue in Millions : 253
Growth (%) : 0
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 305
2020 Revenue in Millions : 252
Growth (%) : 21
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 269
2021 Revenue in Millions : 305
Growth (%) : -12
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 238
2022 Revenue in Millions : 269
Growth (%) : -12
Main Therapeutic Indication : Anticoagulants
Currency : USD
2014 Revenue in Millions : 1.40%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anticoagulants
Currency : USD
2015 Revenue in Millions : 364
2014 Revenue in Millions : 335
Growth (%) : -8%
Main Therapeutic Indication : Blood Disorders
Currency : USD
2016 Revenue in Millions : 318
2015 Revenue in Millions : 335
Growth (%) : -5
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 306
2016 Revenue in Millions : 318
Growth (%) : -4
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 293
2017 Revenue in Millions : 306
Growth (%) : -4%
